bioTheranostics Adds Chief Commercial Officer & VP of Corporate Development
Strategic hiring of industry veterans supports company’s continued growth as a leader in solutions for metastatic cancer
July 25, 2012 bioTheranostics, Inc., a provider of solutions for metastatic cancer through the development of innovative oncology diagnostic tests, today announced that Mary Jo Mullen, chief commercial officer, and Isaac J. Bright, M.D., vice president, corporate development, have joined the company’s senior management team.
According to Richard Ding, CEO of bioTheranostics, the addition of Mullen and Bright strengthens the company’s executive team as it plays an increasingly important role in delivering personalized medicine technologies for metastatic cancer—from diagnosis of primary tumor site with its industry-leading CancerTYPE ID® molecular classifier through predictive biomarker testing with PRÉCISSM Precision Medicine biomarker profiles.
“Mary Jo Mullen and Isaac Bright bring a wealth of talent, skills, and industry expertise to our team,” Ding said. “Their extensive leadership and experience in sales, marketing, and business development with both small and large medical companies enhance our infrastructure, and they will play key roles as we work to change the face of metastatic cancer through the development of innovative molecular diagnostic tests.”
Mullen brings more than 22 years of experience in clinical testing and medical device sales and sales leadership. As chief commercial officer, she will lead the bioTheranostics sales, marketing, and client service teams, and identify new opportunities to showcase the company as the leading provider of solutions for metastatic cancer. Prior to joining bioTheranostics, Mullen held senior-level sales management positions at LabCorp through its acquisition of Genzyme Genetics, a premier reproductive genetics and oncology laboratory, where she managed international business and strategic accounts, as well as directed training for both the genetics and oncology divisions. She also has worked with Phillips Medical Systems and Matria Healthcare. She earned her bachelor’s degree in nursing from the University of Missouri-Columbia and has clinical nursing experience.
Bright comes to bioTheranostics with a decade of progressive experience in business and strategic development in genomic and molecular diagnostics and the medical device industry. As vice president of corporate development, he will play a key role in bioTheranostics’ business development and corporate strategy efforts, enhancing and providing guidance on current business initiatives, as well as developing and implementing long-range company goals. Bright joined bioTheranostics from QuantaLife, a life sciences company that provides advanced genetic analysis systems for research. He led the sale of QuantaLife in 2011 to Bio-Rad Laboratories. Previously, Bright held corporate development and business development leadership roles with Medtronic and an investment banking position with CIBC World Markets. He earned his medical degree from the Stanford University School of Medicine and was a Howard E. Mitchell Fellow at The Wharton School of the University of Pennsylvania.
In other news, the company also recently strengthened its board of directors with the addition of three industry veterans. Brad Smith, former vice chairman of LabCorp, has extensive executive experience in operations, legal, and corporate affairs in the diagnostics and clinical laboratory industry. Brian Armstrong is the chief financial officer for bioMérieux Inc., responsible for all financial aspects of the bioMérieux US operations. Francois Valencony is the managing director of Mérieux Développement, a healthcare investment company based in Lyon, France.
bioTheranostics is the leading solution provider for metastatic cancer management, leveraging its unique expertise in expression profiling to develop a growing array of molecular diagnostic tests for cancer patients. The company operates a CLIA-certified, CAP-accredited diagnostic laboratory to perform its proprietary tests: the CancerTYPE ID® molecular classification test; PRÉCISSM Precision Medicine, which includes biomarker profiles for non-small cell lung and colorectal cancers; and Breast Cancer IndexSM, which quantifies risk of recurrence of estrogen receptor positive, lymph node negative breast cancer. bioTheranostics, a bioMérieux company, is based in San Diego. For more information, visit www.biotheranostics.com.